Autolus Therapeutics Plc · NASDAQ:AUTL
Autolus Therapeutics — Investor Presentation (August 2026)
35 slides from Autolus Therapeutics's investor presentation, August 2026
Slide 1: Developing Next Generation Programmed T Cell Therapies
Developing Next Generation Programmed T Cell Therapies August 2026 For Investor communication only. Not for use in Autolus.com product promotion.
Slide 2: Disclaimer
Developing and Delivering a New Generation of T Cell Therapies Disclaimer These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical fact
Slide 3: Autolus is positioned for value creation
Developing and Delivering a New Generation of T Cell Therapies Autolus is positioned for value creation Obe-cel product franchise supports multiple growth opportunities Initial Indication: Adult r/r B-ALL Pipeline expansion opportunities Strong execution and market expansion grow future commercial p
Slide 4: Autolus is a leader in CAR T manufacturing & product delivery
Developing and Delivering a New Generation of T Cell Therapies Autolus is a leader in CAR T manufacturing & product delivery Executing on manufacturing and product delivery in the first year of launch: Manufacturing success rate >90% Fast, reliable and consistent product delivery No capacity l
Slide 5: AUCATZYL
AUTOLUS’ FIRST APPROVED PRODUCT AUCATZYL® A potentially best-in-class, standalone CD19 CAR T cell therapy
Slide 6: AUCATZYL is gaining traction in US and UK markets
Developing and Delivering a New Generation of T Cell Therapies AUCATZYL® is gaining traction in US and UK markets AUCATZYL Global Net Product Revenue Q2 2026 1H 2026 $45.7 million $71.9 million +119% year-over-year +140% year-over-year Penetration into US market deepening with 82 U.S. Authorized Tre
Slide 7: FELIX trial published in New England Journal of Medicine
Developing and Delivering a New Generation of T Cell Therapies FELIX trial published in New England Journal of Medicine1 Favourable response rate and tolerability, despite challenging patient population High overall response rate with deep molecular responses Excellent tolerability profile • Durable
Slide 8: Data continue to show long term remissions in r/r adult B-ALL
Developing and Delivering a New Generation of T Cell Therapies Data continue to show long term remissions in r/r adult B-ALL At 24 months, overall survival probability was 46.0% Jae H Park et al, EHA 2025, oral presentation #S113 8
Slide 9: Duration of response: median 42.6 months at last data cut
Developing and Delivering a New Generation of T Cell Therapies Duration of response: median 42.6 months at last data cut More than half of patients still in remission at 24 months Jae H Park et al, EHA 2025, oral presentation #S113 9
Slide 10: ASTCT 2026: AUCATZYL patient characteristics in real world setting
Developing and Delivering a New Generation of T Cell Therapies ASTCT 2026: AUCATZYL® patient characteristics in real world setting ROCCA Consortium registry covers approximately 60% of U.S. commercial patients at data cutoff of January 2026 No patient drop off between 1st & 2nd infusion 96 patients
Slide 11: ASTCT 2026: AUCATZYL real world data consistent with FELIX
Developing and Delivering a New Generation of T Cell Therapies ASTCT 2026: AUCATZYL® real world data consistent with FELIX pivotal trial ROCCA Consortium registry covers approximately 60% of U.S. commercial patients at data cutoff of January 2026 Bone Marrow Disease Response 100% 80% 60% 69% 66% 40%
Slide 12: Expanding the obe-cel opportunity
Expanding the obe-cel opportunity Deep value program with potentially broad applicability
Slide 13: Pipeline supports growth with multiple development opportunities
Developing and Delivering a New Generation of T Cell Therapies Pipeline supports growth with multiple development opportunities Near-Term Growth Drivers Product Indication Target Preclinical Phase 1 Phase 2/Pivotal Approved Status AUCATZYL® FDA, MHRA^ & EC Adult ALL CD19 (obe-cel) approved† obe-cel
Slide 14: Growing the obe-cel franchise commercial opportunity
Developing and Delivering a New Generation of T Cell Therapies Growing the obe-cel franchise commercial opportunity Robust clinical database and demonstrated commercial capabilities position Autolus for efficient path in new indications Graphic is illustrative, not to scale Significant ~300,0003 Mar
Slide 15: Pediatric r/r B-ALL development strategy
Developing and Delivering a New Generation of T Cell Therapies Pediatric r/r B-ALL development strategy Regenerative Medicine Advanced Therapy (RMAT) designation supports development pathway Development Rationale: CATULUS Phase 1 CATULUS Phase 2 High Unmet Medical Need • 30 patients, SAT • Kymriah a
Slide 16: CATULUS Phase 1 data support progressing into Phase 2
Developing and Delivering a New Generation of T Cell Therapies CATULUS Phase 1 data support progressing into Phase 2 Safety profile of obe-cel in pediatric patients consistent with that previously reported in adults *One patient experienced both Grade 3 CRS and Grade 3 ICANS. ‡Time to onset (days) =
Slide 17: CATULUS data demonstrate promising initial efficacy in pediatric patients
Developing and Delivering a New Generation of T Cell Therapies CATULUS data demonstrate promising initial efficacy in pediatric patients At median follow-up of 8.8 months in pediatric r/r B-ALL patients: ORR was 95.5%; CR was achieved in 90.9% Swimmer plot showing disease assessments in the B-ALL co
Slide 18: Opportunity in U.S. to be the preferred treatment for all age groups
Investor Event: Spotlight on ALL Business Opportunity in U.S. to be the preferred treatment for all age groups in r/r B-ALL with pediatric label expansion Disease Stages Ages Refractory 1L Relapse 2L+ Relapse 0-18* Obe-cel 18+ 0-25 Tisa-cel 26+ 0-18 Brexu-cel 18+ Source: USPI Features, Kymriah *Assu
Slide 19: MOA and commercial capabilities are key differentiators in AID
Developing and Delivering a New Generation of T Cell Therapies MOA and commercial capabilities are key differentiators in AID Obe-cel is the only CD19 CAR approved in other indications that is now being tested for autoimmune disease Autolus Potential Advantage Favorable tolerability to drive accepta
Slide 20: CARSLYLE: Obe-cel shows promise as a new approach for SLE/LN
Developing and Delivering a New Generation of T Cell Therapies 20 CARSLYLE: Obe-cel shows promise as a new approach for SLE/LN 50 million cell dose selected as recommended Phase 2 dose Patient population: • Patients were significantly impaired with their kidney function and had across the board some
Slide 21: CARSLYLE: Obe-cel is well tolerated with no ICANS or Grade ≥2 CRS
Developing and Delivering a New Generation of T Cell Therapies CARSLYLE: Obe-cel is well tolerated with no ICANS or Grade ≥2 CRS Infused adult patients, 50M (n=6) Infused adult patients, 100M (n=3) Any grade, n (%) Grade ≥3, n (%) Any grade, n (%) Grade ≥3, n(%) CRS 3 (50.0) 0 3 (100) 0 ICANS 0 0 0
Slide 22: 5 of 6 patients achieved DORIS with median onset of 5.1 months
Developing and Delivering a New Generation of T Cell Therapies 5 of 6 patients achieved DORIS with median onset of 5.1 months Swimmer plot showing DORIS over time in the 50M adult cohort (n=6) Patient 1 Patient 2 50M adults (n=6) Patient 3 Patient 4 Patient 5 Patient 6 1 2 3 4 5 6 7 8 9 10 11 12 Tim
Slide 23: Clinically meaningful reduction in SLEDAI-2K score observed
Developing and Delivering a New Generation of T Cell Therapies Clinically meaningful reduction in SLEDAI-2K score observed 50M adult cohort (n=6) 100M adult cohort (n=3) Patient 1 Patient 2 Patient 3 Patient 1 Patient 2 30 30 30 30 30 25 25 25 25 25 SLEDAI-2K score SLEDAI-2K score SLEDAI-2K score SL
Slide 24: Lupus nephritis development strategy
Developing and Delivering a New Generation of T Cell Therapies Lupus nephritis development strategy First Approval Label Expansion Leveraging a fast to market strategy CARLYSLE Trial LUMINA Trial Ph3 Randomized Development Rationale Phase 1 Phase 2 Controlled vs SoC • LN is assessed by quantitative
Slide 25: Phase 2 LUMINA trial supports efficient path to market
Developing and Delivering a New Generation of T Cell Therapies Phase 2 LUMINA trial supports efficient path to market Evaluating severe, refractory lupus nephritis (LN) Obe-cel Obe-cel Manufacturing Infusion Monthly safety and L Day-5 Day 1 efficacy follow-up Screening Leukapheresis Lymphodepletion
Slide 26: Multiple sclerosis development strategy
Developing and Delivering a New Generation of T Cell Therapies Multiple sclerosis development strategy • Anticipate a Establish Phase 1 Clinical Proof of Concept in MS randomised phase 2/3 study design as 3 x 6 dose escalation design - a higher dose path to approval may be required for CNS effect In
Slide 27: BOBCAT study population represents the highest unmet need in MS
Developing and Delivering a New Generation of T Cell Therapies BOBCAT study population represents the highest unmet need in MS Aspirational – improving disability and moving back on 1. Progressive forms of MS EDSS timeline including all forms of Transformational – halting disease progressive MS with
Slide 28: BOBCAT Phase 1 study design
Developing Next Generation Programmed T Cell Therapies BOBCAT Phase 1 study design Sample size: 12-18 patients infused with obe-cel Dosing: Standard Flu/Cy based preconditioning and a single infusion of 100 or 200 million CART cells and flexibility to adjust dose up or down Primary endpoint: •Safety
Slide 29: Upcoming data update: BOBCAT Trial in Progressive MS
Developing and Delivering a New Generation of T Cell Therapies Upcoming data update: BOBCAT Trial in Progressive MS Patient and physician interest is high; trial enrollment continues on track Q1 2027 2H 2027 Preliminary Phase 1 Data: Targeting ACTRIMS Full Phase 1 Data • Total 12 patients • Total 18
Slide 30: Pipeline-in-a-product: expanding obe-cel's potential beyond adult B-ALL
Developing and Delivering a New Generation of T Cell Therapies Pipeline-in-a-product: expanding obe-cel's potential beyond adult B-ALL Anticipated news flow and data catalysts for ongoing pipeline programs Timing Program Update Indication Trial CARLYSLE End of 2026 Obe-cel Longer-term follow up data
Slide 31: Financial Highlights
Financial Highlights
Slide 32: Financial summary – key metrics
Developing and Delivering a New Generation of T Cell Therapies Financial summary – key metrics* USD ($’ 000) Q2 2026 Q2 2025 Variance Product revenue, net 45,672 20,923 24,749 Cost and operating expenses: Cost of sales (20,468) (24,445) 3,977 Research and development expenses, net (27,898) (27,430)
Slide 33: Executing to plan with momentum in 2026
Developing and Delivering a New Generation of T Cell Therapies Executing to plan with momentum in 2026 2026 Expectations & Financial Guidance Commercial Expansion Achieved: Increase commercial Gross Margin footprint in the US to more FY 2026 Net than 80 treatment centers Product Revenue Achieved: Sh
Slide 34: Path to profitability in the r/r B-ALL business
Developing and Delivering a New Generation of T Cell Therapies Path to profitability in the r/r B-ALL business Optimizing the operating model and driving cost efficiency Increasing volumes and operational efficiency initiatives producing gross margin improvements We are here Launch: Establish consis
Slide 35: Thank you
Thank you Investor Contact: A.Cray@autolus.com Executive Director, Investor Relations & External Communications Autolus.com
Autolus Therapeutics — Investor Presentation (August 2026) on 6ix